Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine

High-risk Myelodysplastic syndromes (MDS) represent therapeutical challenges and are usually managed with hypomethylating agents such as azacitidine. Given the lack of data in the literature concerning azacitidine effects on bone marrow, we retrospectively analyzed 57 high-risk MDS cases in order to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pescia, Carlo, Boggio, Francesca, Croci, Giorgio Alberto, Cassin, Ramona, Barella, Marco, Pettine, Loredana, Reda, Gianluigi, Sabattini, Elena, Finelli, Carlo, Gianelli, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584458/
https://www.ncbi.nlm.nih.gov/pubmed/34768330
http://dx.doi.org/10.3390/jcm10214809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584458/
https://www.ncbi.nlm.nih.gov/pubmed/34768330
http://dx.doi.org/10.3390/jcm10214809

Ejemplares similares